Suchergebnisse - "Domingo, Jason"

PubPharm (6)

1

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine

enthalten in: Gastroenterology | 2023

von Liu, Z. | Alexander, J. | Lin, K. | +70

2

COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP) : a multicentre, prospective, case-control study

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Alexander, J. | Liu, Z. | Muñoz Sandoval, D. | +67

3

COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP) : a multicentre, prospective, case-control study

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Alexander, J. | Kennedy, N. | Ibraheim, H. | +60

CommentIn: Lancet Gastroenterol Hepatol. 2022 Apr;7(4):280-282. - PMID 35123675

4

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

enthalten in: Nature | 2022

von Meng, B. | Abdullahi, A. | Ferreira, I. | +154

UpdateOf: Res Sq. 2022 Jan 17;:. - PMID 35075452

5

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

enthalten in: Nature | 2021

von Collier, D. | Ferreira, I. | Kotagiri, P. | +126

6

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

enthalten in: Nature | 2021

von Collier, D. | De Marco, A. | Ferreira, I. | +138

UpdateOf: medRxiv. 2021 Feb 15;:. - PMID 33619509

1
[1]